Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura
- 1 April 1990
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 74 (4) , 457-464
- https://doi.org/10.1111/j.1365-2141.1990.tb06335.x
Abstract
Summary: We have previously observed calpain activity (calcium‐dependent cysteine protease) in sera from patients with acute thrombotic thrombocytopenic purpura (TTP). The calpain activity was not present following recovery and was not detected in other thrombocytopenic disorders. We postulated that this enzyme could participate in the pathogenesis of TTP. Because other investigators have demonstrated abnormalities of von Willebrand factor (vWF) in patients with TTP, we proposed that calpain might interact with vWF in TTP. To challenge this hypothesis, we measured the binding of untreated and calpain‐treated vWF to normal and ADP or calpain activated platelets. Untreated vWF bound in a specific and saturable fashion to activated platelets, but only at low (30 μm) calcium concentrations. Von Willebrand factor did not bind to activated platelets at physiological (2 mm) calcium concentrations. Calpain proteolysis of vWF changed the binding characteristics of the vWF so that it had greatly increased binding to both ADP and calpain activated platelets. The calpain‐proteolysed vWF bound to activated platelets at both low and physiological calcium concentrations, and was capable of causing platelet aggregation. The calpain‐proteolysed vWF bound to the activated platelets via glycoproteins IIb/IIIa as demonstrated by inhibition studies using monoclonal antibodies against glycoproteins IIb/IIIa and Ib. It also had a high binding affinity and was capable of inhibiting the binding of radiolabelled fibrinogen to the activated platelets at physiological calcium concentrations. Calpain also proteolysed fibrinogen, but the calpain altered fibrinogen had normal platelet reactivity.These studies provide further insight into the pathogenesis of the platelet aggregation of thrombotic thrombocytopenic purpura. Calpain proteolyses vWF and can produce the characteristic loss of large multimers seen on sodium dodecyl sulphate (SDS)‐agarose gel electrophoresis. The altered vWF is highly reactive with activated platelets and binds to platelet glycoproteins IIb/IIIa and participates in formation of the platelet aggregates that characterize this disease.Keywords
This publication has 23 references indexed in Scilit:
- Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 1987
- Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor.Journal of Clinical Investigation, 1986
- Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigenThrombosis Research, 1985
- Detection of a Platelet-Agglutinating Factor in Thrombotic Thrombocytopenic PurpuraAnnals of Internal Medicine, 1984
- Purification of the factor VIII complexThrombosis Research, 1984
- Cleavage of fibrinogen by human platelet calcium-activated proteaseThrombosis Research, 1984
- Platelets have more than one binding site for von Willebrand factor.Journal of Clinical Investigation, 1983
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982
- THROMBOTIC THROMBOCYTOPENIC PURPURAMedicine, 1966
- THROMBOHEMOLYTIC THROMBOCYTOPENIC PURPURAArchives of internal medicine (1960), 1954